Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study

被引：1

作者：

Fili, Carla ^{[1
]}

Finelli, Carlo ^{[2
]}

Gobbi, Marco ^{[3
]}

Martinelli, Giovanni ^{[2
]}

Iacobucci, Ilaria ^{[2
]}

Ottaviani, Emanuela ^{[2
]}

Cocco, Lucio ^{[4
]}

Follo, Matilde ^{[4
]}

Candoni, Anna ^{[5
,6
]}

Simeone, Erika ^{[5
,6
]}

Miglino, Maurizio ^{[3
]}

Lauria, Francesco ^{[7
]}

Bocchia, Monica ^{[7
]}

Defina, Marzia ^{[7
]}

Clissa, Cristina ^{[2
]}

Lanza, Francesco ^{[8
]}

Curti, Antonio ^{[2
]}

Paolini, Stefania ^{[2
]}

Spedini, PierAngelo ^{[8
]}

Skert, Cristina ^{[1
]}

Bergonzi, Cesare ^{[1
]}

Malagola, Michele ^{[1
]}

Peli, Annalisa ^{[1
]}

Turra, Alessandro ^{[1
]}

Cattina, Federica ^{[1
]}

Colombi, Chiara ^{[1
]}

Russo, Domenico ^{[1
]}

机构：

[1] Univ Brescia, Chair Haematol, Unit Blood Dis & Cell Therapies, Brescia, Italy

[2] Univ Bologna, Inst Haematol & Med Oncol L&A Seragnoli, I-40126 Bologna, Italy

[3] Univ Genoa, Genoa, Italy

[4] Univ Bologna, Dept Human Anat Sci, I-40126 Bologna, Italy

[5] Univ Hosp Udine, Chair Haematol, Udine, Italy

[6] Univ Hosp Udine, Div Haematol, Udine, Italy

[7] Univ Siena, I-53100 Siena, Italy

[8] Hosp Cremona, Div Haematol, Cremona, Italy

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

10.1182/blood.V116.21.4029.4029

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1642 / 1642

页数：1

共 50 条

[1] ADDITION OF LENALIDOMIDE TO AZACITIDINE IN HIGHER RISK MYELODYSPLASTIC SYNDROMES. LONG-TERM RESULTS OF A RANDOMIZED PHASE II MULTICENTER STUDY
Finelli, C.
Clissa, C.
Follo, M.
Barraco, M.
Mongiorgi, S.
Avanzini, P.
Bosi, C.
Castagnari, B.
Candoni, A.
Crugnola, M.
Giannini, M. B.
Gobbi, M.
Leonardi, G.
Rigolin, G. M.
Russo, D.
Tosi, P.
Pellagatti, A.
Boultwood, J.
Cocco, L.
Cavo, M.
LEUKEMIA RESEARCH, 2017, 55 : S50 - S51
[2] Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM
Natarajan-Ame, Shanti
Park, Sophie
Ades, Lionel
Vey, Norbert
Guerci-Bresler, Agnes
Cahn, Jean-Yves
Etienne, Gabriel
Bordessoule, Dominique
Ravoet, Christophe
Legros, Laurence
Cheze, Stephane
Stamatoullas, Aspasia
Berger, Elisabeth
Schmidt, Aline
Charbonnier, Aude
Chaury, Marie-Pierre
Braun, Thorsten
Fenaux, Pierre
Dreyfus, Francois
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (02) : 232 - 237
[3] CLINICAL RESPONSE TO THE ASSOCIATION OF AZACITIDINE AND LENALIDOMIDE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES. A RANDOMIZED PHASE II MULTICENTER STUDY
Finelli, C.
Clissa, C.
Follo, M. Y.
Stanzani, M.
Parisi, S.
Avanzini, P.
Bosi, C.
Castagnari, B.
Candoni, A.
Crugnola, M.
Giannini, M. B.
Gobbi, M.
Leonardi, G.
Rigolin, G. M.
Russo, D.
Tosi, P.
Visani, G.
Cocco, L.
Cavo, M.
LEUKEMIA RESEARCH, 2015, 39 : S50 - S50
[4] Results of heme arginate treatment of myelodysplastic syndromes. A multicenter phase II study of the ''French group of myelodysplastic syndromes''.
Rochant, H
Fenaux, P
Guerci, A
Coiffier, B
Dreyfus, F
Belanger, C
Elonen, E
Kangasaho, M
Jouhikainen, T
BLOOD, 1996, 88 (10) : 3566 - 3566
[5] Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes
Montalban-Bravo, Guillermo
Jabbour, Elias
Class, Caleb
Short, Nicholas J.
Kanagal-Shamanna, Rashmi
Kadia, Tapan M.
Borthakur, Gautam M.
Pemmaraju, Naveen
Sasaki, Koji
Estrov, Zeev E.
Cortes, Jorge E.
Ravandi, Farhad
Alvarado, Yesid
Komrokji, Rami S.
Sekeres, Mikkael A.
Steensma, David P.
DeZern, Amy E.
Roboz, Gail J.
Yang, Hui
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
BLOOD, 2019, 134
[6] Efficacy of growth factors compared to chemotherapy in low-risk myelodysplastic syndromes.
Golshayan, A
Fu, AZ
Kattan, MW
Brown, S
Maciejewski, JP
Sekeres, MA
BLOOD, 2005, 106 (11) : 713A - 714A
[7] Association of Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes. Final Results of a Randomized Phase II Multicenter Study
Finelli, Carlo
Clissa, Cristina
Follo, Matilde
Stanzani, Marta
Parisi, Sarah
Mongiorgi, Sara
Avanzini, Paolo
Bosi, Costanza
Castagnari, Barbara
Candoni, Anna
Crugnola, Monica
Giannini, Maria Benedetta
Gobbi, Marco
Leonardi, Giovanna
Rigolin, Glan Matteo
Russo, Domenico
Tosi, Patrizia
Visani, Giuseppe
Cocco, Lucio
Cavo, Michele
BLOOD, 2015, 126 (23)
[8] A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes.
Sekeres, MA
Fu, AZ
Maciejewski, JP
Golshayan, AR
Kalaycio, M
Kattan, MW
BLOOD, 2005, 106 (11) : 711A - 711A
[9] ASSOCIATION OF AZACITIDINE AND LENALIDOMIDE (COMBINATION VS SEQUENTIAL TREATMENT) IN HIGH-RISK MYELODYSPLASTIC SYNDROMES. UPDATE OF THE RESULTS OF A RANDOMIZED PHASE II MULTICENTER STUDY
Finelli, C.
Clissa, C.
Follo, M. Y.
Stanzani, M.
Parisi, S.
Mongiorgi, S.
Avanzini, P.
Bosi, C.
Castagnari, B.
Candoni, A.
Crugnola, M.
Giannini, M. B.
Gobbi, M.
Leonardi, G.
Rigolin, G. M.
Russo, D.
Tosi, P.
Giuseppe, V.
Cocco, L.
Cavo, M.
HAEMATOLOGICA, 2015, 100 : 241 - 241
[10] A pilot study of treatment with mesterlone, prednisone and low-dose thalidomide for patients with Myelodysplastic syndromes.
Aguayo, Alvaro
Garcia-Alvarez, Eunice
Crespo-Solis, Erick
Martinez-Banos, Deborah
Lopez-Karpovitch, Xavier
BLOOD, 2007, 110 (11) : 221B - 221B

← 1 2 3 4 5 →